Toll Free: 1-888-928-9744
Published: Jul, 2016 | Pages:
32 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 2.7.11.30) - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 2.7.11.30) - Pipeline Review, H2 2016', provides in depth analysis on TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 2.7.11.30) targeted pipeline therapeutics. The report provides comprehensive information on the TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 2.7.11.30), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 2.7.11.30) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 2.7.11.30) - The report reviews TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 2.7.11.30) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 2.7.11.30) targeted therapeutics and enlists all their major and minor projects - The report assesses TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 2.7.11.30) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 2.7.11.30) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 2.7.11.30) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 2.7.11.30) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 2.7.11.30) Overview 6 Therapeutics Development 7 TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 2.7.11.30) - Products under Development by Stage of Development 7 TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 2.7.11.30) - Products under Development by Therapy Area 8 TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 2.7.11.30) - Products under Development by Indication 9 TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 2.7.11.30) - Pipeline Products Glance 10 Early Stage Products 10 TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 2.7.11.30) - Products under Development by Companies 11 TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 2.7.11.30) - Therapeutics Assessment 13 Assessment by Monotherapy/Combination Products 13 Assessment by Mechanism of Action 14 Assessment by Route of Administration 15 Assessment by Molecule Type 17 TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 2.7.11.30) - Companies Involved in Therapeutics Development 19 Eli Lilly and Company 19 Oncodesign SA 20 Oncomatryx Biopharma, S.L. 21 TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 2.7.11.30) - Drug Profiles 22 Antibody to Antagonise TGF Beta Receptor Type 2 for Oncology - Drug Profile 22 Product Description 22 Mechanism Of Action 22 R&D Progress 22 ITD-1 - Drug Profile 23 Product Description 23 Mechanism Of Action 23 R&D Progress 23 OMTX-001 - Drug Profile 24 Product Description 24 Mechanism Of Action 24 R&D Progress 24 Small Molecules to Antagonize Transforming Growth Factor Beta Receptor II for Oncology - Drug Profile 25 Product Description 25 Mechanism Of Action 25 R&D Progress 25 Synthetic Peptides to Antagonize TGF-Beta Receptor for Diabetic Foot Ulcers, Pulmonary Fibrosis and Dermatology - Drug Profile 26 Product Description 26 Mechanism Of Action 26 R&D Progress 26 TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 2.7.11.30) - Dormant Projects 28 TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 2.7.11.30) - Discontinued Products 29 TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 2.7.11.30) - Featured News & Press Releases 30 Nov 14, 2012: Small molecule makes heart cells out of stem cells 30 Appendix 31 Methodology 31 Coverage 31 Secondary Research 31 Primary Research 31 Expert Panel Validation 31 Contact Us 31 Disclaimer 32
List of Tables
Number of Products under Development for, H2 2016 7 Number of Products under Development by Therapy Area, H2 2016 8 Number of Products under Development by Indication, H2 2016 9 Comparative Analysis by Early Stage Products, H2 2016 10 Number of Products under Development by Companies, H2 2016 11 Products under Development by Companies, H2 2016 12 Assessment by Monotherapy/Combination Products, H2 2016 13 Number of Products by Stage and Mechanism of Action, H2 2016 14 Number of Products by Stage and Route of Administration, H2 2016 16 Number of Products by Stage and Molecule Type, H2 2016 18 Pipeline by Eli Lilly and Company, H2 2016 19 Pipeline by Oncodesign SA, H2 2016 20 Pipeline by Oncomatryx Biopharma, S.L., H2 2016 21 Dormant Projects, H2 2016 28 Discontinued Products, H2 2016 29
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.